Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 68

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 68
---
 required to delay, reduce, or terminate some or all of our development programs and clinical trials.
We may also be required to sell or license to other parties rights to develop or commercialize our drug candidate that we would prefer
to retain.

See “Risk
Factors” included herein and in our 2024 Annual Report on Form 10-K for fiscal 2024 filed with the Securities and Exchange
Commission (the “SEC”) on March 28, 2025 for additional discussion of risks associated with our capital
requirements.

Cash Flows for the Three Months Ended March
31, 2025 and 2024

The following table shows
a summary of our cash flows for the three months ended March 31, 2025 and 2024.

    For the Three Months Ended March 31, 

    2025  
    2024 
  
    Net cash flows from operating activities 
    $(1,063,041) 
    $(65,165)
  
    Net cash flows from investing activities 
     -  
     - 
  
    Net cash flows from financing activities 
    $-  
    $45,000 
  
    Net increase (decrease) in cash 
    $(1,063,041) 
    $(35,953)

Net Cash Flows From Operating
Activities:

Net cash used in operating
activities during the three months ended March 31, 2025 was $1,063,041, as compared to net cash used in operating activities of $65,165.
The increase in net cash used in operating activities was primarily related to the changes in our net loss.

Net Cash Flows From Investing
Activities:

No net cash was provided by
or used in investing activities for the three months ended March 31, 2025 and 2024.

Net Cash Flows From Financing Activities:

Net cash provided in financing
activities during the three months ended March 31, 2025 was $0, as compared to net cash provided in financing activities of $45,000. The
decrease in net cash provided was primarily related to no new financing being provided in the current period compared to the prior period.

Off-balance sheet financing arrangements

We have no obligations, assets
or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of